Evruleucel

厄鲁仑赛

Report date: 2024/07/03 21:31:43

Base Information

Drug NameEvruleucel
Drug Alias NameATA188Autologous ATA188Epstein-Barr Virusdirected cytotoxic T lymphocytesEBV-CTLsEBV-targeted T-cell +[9] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsMultiple Sclerosis, Chronic ProgressiveLymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAtara Biotherapeutics IncMemorial Sloan Kettering Cancer Center
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis, Chronic ProgressiveLymphomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A